Possible levomepromazine-clozapine interaction: Two case reports

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 2, 2007, Pages 567-570

  Bugamelli, Francesca ^a   Mandrioli, Roberto ^a   Kenndler, Ernst ^b   Bartoletti, Claudio ^c   Boncompagni, Giancarlo ^d   Raggi, Maria Augusta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF VIENNA   (Austria)

^c Azienda USL di Bologna   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Clozapine; Levomepromazine; Liquid chromatography; Metabolites; Pharmacological interaction; Plasma samples

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLURAZEPAM; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; NEUROLEPTIC AGENT; VALPROIC ACID;

ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; HUMAN; MALE; POLYPHARMACY; SCHIZOPHRENIA; TREATMENT FAILURE;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG INTERACTIONS; HUMANS; MALE; MENTAL DISORDERS; METHOTRIMEPRAZINE; MIDDLE AGED;

EID: 33846847660     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.11.003     Document Type: Article

References (30)

1. Bergermann N., Kopitz J., Kress K.R., and Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 14 (2004) 245-250
2. Cascorbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implications. Eur J Clin Invest 33 (2003) 17-22
3. Casey D.E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99 (1989) 47-53
4. Centorrino F., Baldessarini R.J., Kando J.C., Frankenburg F.R., Volpicelli S.A., and Flood J.G. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 14 (1994) 119-125
5. Dahl S.G., Strandjord R.E., and Sigfusson S. Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. Eur J Clin Pharmacol 11 (1977) 305-310
6. Fang J., Coutts R.T., McKenna K.F., and Baker G.B. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. N-S Arch Pharmacol 358 (1998) 592-599
7. Hals P.A., and Dahl S.G. Effect of levomepromazine and metabolites on debrisoquine hydroxylation in the rat. Pharmacol Toxicol 75 5 (1994) 255-260
8. Hasegawa M., Gutierrez-Esteinou R., and Way L.J. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. Clin Psychopharmacol 13 (1993) 383-390
9. Hasegawa M., Cole P.A., and Meltzer H.Y. Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis. Neuropsychopharmacology 11 (1994) 45-47
10. Kane J., Cooper T.D., Sachar E.J., Halpern F.S., and Bailine S. Clozapine: plasma levels and prolactin response. Psychopharmacology 73 (1981) 184-187
11. Lal S., Nair N.P.V., Cecyre D., and Quirion R. Levomepromazine receptor binding profile in human brain - implications for treatment resistant schizophrenia. Acta Psychiatr Scand 87 (1993) 380-383
12. Lal S., Thavundayil J.X., Vasavan Nair N.P., Annable L., Ng Ying Kin N.M.K., Gabriel A., et al. Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. J Psychiatry Neurosci 31 (2006) 271-279
13. Leadbetter R., Shutty M., Pavalonis D., Vieweg V., Higgins P., and Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 149 (1992) 68-72
14. Loennechen T., Anderson A., Hals P.-.A., and Dahl S.G. High-performance liquid chromatographic determination of levomepromazine and its main metabolites in serum and urine. Ther Drug Monit 12 (1990) 574-581
15. Mercolini L, Bugamelli F, Kenndler E, Boncompagni G, Franchini L, Raggi MA. Simultaneous determination of the antipsychotic drugs levomeproazine and clozapine and their main metabolites in human plasma by a HPLC-UV method with solid-phase extraction. J Chromatogr B in press. ____________________________doi:10.1016/j.jchromb.2006.09.019 (Available on line http://www.sciencedirect.com/science/article/B6X0P-4M3J0X6-1/2/3100b824417b13cfb88bb5722965296c).
16. Olesen O.V., and Linnet K. Contributions of five human cytochrome P450 isoforms to the N-emethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 41 (2001) 823-832
17. Olesen O.V., Thomsen K., Jensen P.N., Wulff C.H., Rasmussen N.A., Refshammer C., et al. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology 117 (1995) 371-378
18. Perry P.J., Miller D.D., Arndt S.V., and Cadoret R.J. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148 (1991) 231-235
19. Prior T.I., Chue P.S., Tibbo P., and Baker G.B. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 9 4 (1999) 301-309
20. Raggi M.A. Therapeutic drug monitoring: chemical-clinical correlations of atypical antipsychotic drugs. Curr Med Chem 9 (2002) 1397-1409
21. Raggi M.A., Bugamelli F., Mandrioli R., De Ronchi D., and Volterra V. Determination of clozapine in human plasma by solid-phase extraction and liquid chromatography with amperometric detection. Chromatographia 47 (1998) 8-12
22. Raggi M.A., Bugamelli F., Mandrioli R., De Ronchi D., and Volterra V. Development and validation of an HPLC method for the simultaneous determination of clozapine and desmethylclozapine in plasma of schizophrenic patients. Chromatographia 49 (1999) 75-80
23. Raggi M.A., Bugamelli F., Sabbioni C., De Ronchi D., Pinzauti S., and Volterra V. An improved HPLC-ED method for monitoring plasma levels of clozapine and its active metabolites in schizophrenic patients. Chromatographia 51 (2000) 147-153
24. Rägo L. Pharmacogenetics and existing therapies. WHO Drug Inf 17 (2003) 84-91
25. Stahl S.M. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret?. J Clin Psychiatry 60 (1999) 425-426
26. Stahl S.M. Psychopharmacology of antipsychotics (1999), Martin Dunitz, London
27. Tapp A., Wood A.E., Secrest L., Erdmann J., Cubberley L., and Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54 1 (2003) 55-59
28. Tyson S.C., DeVane C.L., and Risch S.C. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 152 (1995) 1401-1402
29. Wagstaff A.J., and Bryson H.M. Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 4 (1995) 370-400
30. Winek C.L., Wahba W.W., Winek C.L., and Balzer T.W. Drug and chemical blood-level data 2001. Forensic Sci Int 122 2-3 (2001) 107-123